Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (10): 894-896.DOI: 10.3969/j.issn.1673-8640.2019.10.006

Previous Articles     Next Articles

Clinical distribution and trend of multidrug resistant Acinetobacter baumannii

LI Fusheng1, GUO Qiaomei1, LI Zhifu1, XU Yangyang1, XIN Min2, LOU Jiatao1()   

  1. 1. Department of Clinical Laboratory, Shanghai Chest Hospital,the Chest Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200030,China
    2. Shanghai Jiaotong University School of Medicine,Shanghai 200030,China
  • Received:2018-07-20 Online:2019-10-30 Published:2019-11-01

Abstract: Objective To analyze the clinical distribution and trend of Acinetobacter baumannii(AB) and multidrug resistant Acinetobacter baumannii(MDR-AB) isolated in Shanghai Chest Hospital,and to provide a reference for controlling MDR-AB infection. Methods Totally,499 isolates of AB isolated in Shanghai Chest Hospital from 2015 to 2017 were identified by VITEK MS microbial mass spectrometry identification system. The drug susceptibility test in vitro was carried out by VITEK-2 COMPACT,and the related clinical data were analyzed. Results The detection rate of AB increased from 2015 to 2017(χ2=7.168,P<0.05),while the detection rate of MDR-AB decreased year by year(χ2=35.086,P<0.01). The detection rates of AB and MDR-AB in male patients were higher than those in female patients(P>0.05). The detection rates of AB and MDR-AB all reached the highest in patients of 60-69 years old,and there was a yearly upward trend of MDR-AB detection rate in patients of 70-79 years old(χ2=6.775,P<0.05). The specimens with AB and MDR-AB were mainly sputum specimens,most of which were from intensive care unit(ICU) of Shanghai Chest Hospital. Conclusions With the increasing of AB detection rate,the monitoring of MDR-AB should be strengthened,and disinfection and isolation should be done well to control the development of multidrug resistant isolates.

Key words: Acinetobacter baumannii, Multidrug resistance, Detection rate, Change trend

CLC Number: